A universal carrier test for the long tail of Mendelian disease
Abstract
Mendelian disorders are individually rare but collectively common, forming a ‘long tail’ of genetic disease. A single highly accurate assay for this long tail would allow the scaling up of the Jewish community’s successful campaign of population screening for Tay–Sachs disease to the general population, thereby improving millions of lives, greatly benefiting minority health and saving billions of dollars. This need has been addressed by designing a universal carrier test: a non-invasive, saliva-based assay for more than 100 Mendelian diseases across all major population groups. The test has been exhaustively validated with a median of 147 positive and 525 negative samples per variant, demonstrating a multiplex assay whose performance compares favourably with the previous standard of care, namely blood-based single-gene carrier tests. Because the test represents a dramatic reduction in the cost and complexity of large-scale population screening, an end to many preventable genetic diseases is now in sight. Moreover, given that the assay is inexpensive and requires only a saliva sample, it is now increasingly feasible to make carrier testing a routine part of preconception care.
Keywords: carrier testing, Mendelian disease, population screening, preconception, preventive medicine, reproductive health
To access this article, please choose from the options below
Balaji S Srinivasan taught computational genomics and statistics at Stanford before becoming Chief Technology Officer (CTO) of Counsyl. His research interests include machine learning, personalized medicine and the biology and diagnosis of rare genetic variants.
PII: S1472-6483(10)00336-6
doi:10.1016/j.rbmo.2010.05.012
© 2010 Reproductive Healthcare Ltd. Published by Elsevier Inc All rights reserved.
